Compare Entegris Inc (ENTG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Neurocrine Biosciences Inc — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Neurocrine Biosciences Inc for 23 Days on average.
| ENTG | NBIX | |
|---|---|---|
Market Cap | $24.78B | $14.36B |
Volume | 2,648,320 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $184.00 | $185.50 |
52-Week Low | $68.80 | $123.10 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | $27.99B | $14.37B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.48% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 29, 2026. Revenue for 2025 was $3.20B, with a net income margin of 7.37%. Analyst consensus is strongly bullish, with a price target of $182.43, indicating a 12.5% upside. Recent news highlights strong AI-driven semiconductor demand and institutional buying interest.
The outlook for ENTG is positive, supported by robust earnings performance and growing demand in the semiconductor sector. Key opportunities include expansion in AI-related markets and operational efficiency gains. Risks involve high valuation multiples, competitive pressures, and sensitivity to semiconductor industry cycles. Investors should weigh the strong analyst support against potential market volatility and execution challenges.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
